格列齐特缓释片的临床应用

Clinical application of slow-released-gliclazide

口服降糖药物是2型糖尿病(T2DM)的主要治疗药物,磺脲类药物是目前疗效肯定、应用最广泛的口服降糖药之一。格列齐特是临床常用的第二代磺脲类口服降糖药,其在T2DM患者中的良好作用已得到公认,而缓释片作为一种新的剂型,相对于普通片,进一步提高了患者服药的依从性,得到医师和患者的双重信赖,格列齐特不仅具有持久、有效的降血糖作用,还有独特的抗氧化应激、减少血小板凝聚作用,而且能够减轻胰岛素抵抗、改善胰岛β细胞功能,从而延缓病情发展和减少糖尿病慢性并发症的发生。

Oral hypoglycemic drugs are the main drugs for type 2 diabetes mellitus （T2DM）. At present, sulfonylurea drugs are one of the most commonly used and effective oral medications. As a second- generation sulfonylurea oral hypoglycemic agents, gliclazide has been well acknowledged in T2DM patients with good effect. Compared with the ordinary tablet, a new dosage form of slow-released-gliclazide can, further im- prove the compliance of patients and has been trusted through clinics. Gliclazide not only has longterm effect on hypoglycemic, but also has a unique ablitity of anti-oxidant stress, reducing platelet aggregation and insulin re- sistance （IR） , improving islet β cell function, thereby slowing the progression of disease and reducing the in- cidence of complications.